What are the detailed clinical findings associated with each valvular heart disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Valvular Heart Diseases: Detailed Clinical Findings

All patients with known or suspected valvular heart disease require a meticulous history and physical examination, followed by transthoracic echocardiography (TTE) as the standard diagnostic test, with ECG and chest x-ray providing supportive information 1, 2.

Initial Clinical Evaluation Framework

The diagnostic approach prioritizes:

  • Physical examination to identify characteristic murmurs and assess severity
  • TTE with 2D imaging and Doppler for definitive diagnosis and hemodynamic assessment
  • ECG to confirm rhythm and identify chamber abnormalities
  • Chest x-ray to evaluate pulmonary congestion and cardiac silhouette 1, 2

Aortic Stenosis (AS): Clinical Findings

Physical Examination

  • Harsh systolic crescendo-decrescendo murmur at right upper sternal border radiating to carotids
  • Delayed and diminished carotid upstroke (pulsus parvus et tardus)
  • Sustained apical impulse (LV hypertrophy)
  • Paradoxical splitting of S2 in severe cases
  • S4 gallop common

Symptoms (Classic Triad)

  • Exertional dyspnea and heart failure
  • Angina (even without coronary disease)
  • Syncope or presyncope with exertion

ECG Findings

  • Left ventricular hypertrophy with strain pattern
  • Left atrial enlargement
  • Conduction abnormalities (left bundle branch block)

Hemodynamic Criteria for Severity

  • Severe AS: Peak velocity ≥4 m/s, mean gradient ≥40 mmHg, valve area <1.0 cm² 1

Aortic Regurgitation (AR): Clinical Findings

Physical Examination

  • High-pitched, blowing diastolic murmur at left sternal border (best heard with patient leaning forward)
  • Wide pulse pressure with bounding peripheral pulses
  • Displaced, hyperdynamic apical impulse
  • Austin Flint murmur (low-pitched diastolic rumble at apex in severe AR)
  • Multiple eponymous peripheral signs in chronic severe AR

Symptoms

  • Exertional dyspnea
  • Orthopnea and paroxysmal nocturnal dyspnea
  • Palpitations (awareness of forceful heartbeat)
  • Angina in advanced cases

ECG Findings

  • Left ventricular hypertrophy (volume overload pattern)
  • Left atrial enlargement in chronic cases

Chest X-ray

  • Cardiomegaly with LV prominence
  • Dilated ascending aorta

Mitral Stenosis (MS): Clinical Findings

Physical Examination

  • Low-pitched diastolic rumble at apex with presystolic accentuation (if in sinus rhythm)
  • Opening snap after S2 (closer to S2 indicates more severe stenosis)
  • Loud S1
  • Right ventricular heave if pulmonary hypertension present

Symptoms

  • Exertional dyspnea (most common presenting symptom)
  • Orthopnea and paroxysmal nocturnal dyspnea
  • Hemoptysis
  • Atrial fibrillation with risk of thromboembolism
  • Hoarseness (Ortner syndrome from LA enlargement)

ECG Findings

  • Atrial fibrillation is extremely common 3, 4
  • Left atrial enlargement (P mitrale if in sinus rhythm)
  • Right ventricular hypertrophy in advanced disease

Hemodynamic Criteria

  • Severe MS: Valve area <1.0 cm² 1
  • Moderate MS: Valve area 1.0-1.5 cm²

Mitral Regurgitation (MR): Clinical Findings

Physical Examination

  • Holosystolic blowing murmur at apex radiating to axilla
  • Displaced, hyperdynamic apical impulse
  • S3 gallop common
  • Soft S1 in severe cases

Symptoms

  • Exertional dyspnea and fatigue
  • Orthopnea
  • Atrial fibrillation common 3
  • Symptoms may be insidious in chronic primary MR

ECG Findings

  • Left atrial enlargement
  • Atrial fibrillation
  • Left ventricular hypertrophy (volume overload)

Distinction by Phenotype

The 2025 guidelines distinguish atrial vs. ventricular secondary MR phenotypes, which affects treatment strategy 5:

  • Atrial SMR: Associated with atrial fibrillation, preserved LV function
  • Ventricular SMR: Associated with LV dysfunction, ischemic or dilated cardiomyopathy

Tricuspid Regurgitation (TR): Clinical Findings

Physical Examination

  • Holosystolic murmur at left lower sternal border, increases with inspiration (Carvallo sign)
  • Prominent v-waves in jugular venous pulse
  • Hepatomegaly with systolic pulsations
  • Peripheral edema and ascites

Symptoms

  • Right-sided heart failure symptoms
  • Abdominal distension and discomfort
  • Peripheral edema
  • Fatigue

ECG Findings

  • Right atrial enlargement
  • Atrial fibrillation
  • Right ventricular hypertrophy if pulmonary hypertension present

Key Clinical Point

Early referral is emphasized for TR evaluation, with structured assessment of RV function and pulmonary pressures 5. Severe RV dysfunction or precapillary pulmonary hypertension are contraindications to transcatheter intervention.

Common Pitfalls and Caveats

Symptom Assessment

Patients often deny symptoms because they gradually limit activity over years to match progressive valve dysfunction 2. Exercise stress testing helps identify truly symptomatic patients with equivocal histories 2.

Severity Discordance

Some patients have symptoms or end-organ damage without meeting strict hemodynamic criteria for "severe" disease, while others remain asymptomatic despite apparently severe VHD 1. Clinical judgment incorporating multiple parameters is essential.

Associated Findings Across All Valve Lesions

  • Congestive heart failure occurs in approximately 60% of cases except degenerative AR 3
  • Atrial fibrillation is particularly prominent in MS but common across all lesions 3, 4
  • Tricuspid regurgitation frequently accompanies severe mitral valve disease 4
  • Hypertension is associated with 50% of MR and degenerative AR cases 3

Follow-Up Surveillance Intervals

For asymptomatic patients with normal LV function 1:

Aortic Stenosis

  • Mild (Vmax 2.0-2.9 m/s): Every 3-5 years
  • Moderate (Vmax 3.0-3.9 m/s): Every 1-2 years
  • Severe (Vmax ≥4 m/s): Every 6-12 months

Aortic Regurgitation

  • Mild: Every 3-5 years
  • Moderate: Every 1-2 years
  • Severe: Every 6-12 months

Mitral Stenosis

  • Valve area 1.0-1.5 cm²: Every 1-2 years
  • Valve area <1.0 cm²: Every year

Mitral Regurgitation

  • Mild: Every 3-5 years
  • Moderate: Every 1-2 years
  • Severe: Every 6-12 months

Any change in symptoms or physical examination findings warrants immediate repeat TTE 2.

Advanced Diagnostic Testing

When TTE is inconclusive or additional information needed 1, 2:

  • TEE: For valve anatomy, endocarditis, surgical planning
  • CMR: Assesses myocardial fibrosis and ventricular volumes
  • CT: Coronary anatomy, valve calcification, procedural planning
  • Exercise testing: Unmask symptoms, assess hemodynamic response
  • Cardiac catheterization: When noninvasive data inconclusive or discrepant with clinical findings

All echocardiography should be performed in IAC-accredited laboratories 2.

References

3
Research

[Valvular heart diseases in the aged].

Journal of cardiology. Supplement, 1988

5
Research

2025 ESC/EACTS valvular heart disease guidelines: practical updates on mitral and tricuspid regurgitation.

European heart journal supplements : journal of the European Society of Cardiology, 2026

Related Questions

Given the echocardiogram findings of normal left ventricular size with mildly increased wall thickness, ejection fraction 55‑60%, mild biatrial enlargement, dilated sinuses of Valsalva (4.1 cm) and ascending aorta (4.0 cm), aortic sclerosis without stenosis, mild aortic and mitral regurgitation, and moderate tricuspid regurgitation, is this the early stage of heart failure and what additional workup or medication should be pursued?
In which valvular heart diseases is anticoagulation indicated, and which anticoagulant should be used?
What is the appropriate management for a 77-year-old female with chronic obstructive pulmonary disease, hypertension, concentric left ventricular hypertrophy, preserved ejection fraction, severe left atrial enlargement, diastolic dysfunction, mild pulmonary hypertension, aortic valve sclerosis, and mild mitral regurgitation?
Can a patient requiring three concurrent vasopressors undergo surgery for mitral regurgitation?
Should a patient with mild‑to‑moderate native mitral and tricuspid regurgitation receive antibiotic prophylaxis before a tooth extraction?
What are the signs and symptoms of alkaptonuria?
What is the incidence of chronic thromboembolic pulmonary hypertension (CTEPH) after multiple postoperative pulmonary emboli?
Does smoking increase the risk of developing essential thrombocythemia?
What hepatitis B vaccines are available?
What is the anti‑inflammatory activity of fludrocortisone?
Do statins improve metabolic-associated fatty liver disease (MAFLD)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.